AU2011253200A1 - Methods of diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in felines - Google Patents
Methods of diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in felinesInfo
- Publication number
- AU2011253200A1 AU2011253200A1 AU2011253200A AU2011253200A AU2011253200A1 AU 2011253200 A1 AU2011253200 A1 AU 2011253200A1 AU 2011253200 A AU2011253200 A AU 2011253200A AU 2011253200 A AU2011253200 A AU 2011253200A AU 2011253200 A1 AU2011253200 A1 AU 2011253200A1
- Authority
- AU
- Australia
- Prior art keywords
- felines
- diet
- vitamin
- epa
- dha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
METHODS OF DIAGNOSIS, CONTROL AND PROPHYLAXIS OF
INFLAMMATION AND MITIGATION OF INFLAMMATORY CONDITIONS IN
FELINES
Field of the Invention
[0001] The invention relates to methods of diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions, particularly arthritis and joint pain, in felines, comprising measuring particular inflammatory biomarkers. The invention further provides a method to treat or control inflammation comprising administering a diet comprising increased levels of one or more of DHA, EPA, methionine, manganese, vitamin C, vitamin E, and/ or L-carnitine.
Background of the Invention
[0002] Degenerative joint diseases (DJD) or osteoarthritis (OA) in felines has been less recognized than in canines. However, several authors have estimated the occurrence of appendicular DJD in the feline population to range from 16.5% to 64% of older felines. Little is known about the etiology and predisposing factors of feline DJD. Utilizing genomic and proteomic technologies may help provide insight into the disease process and understand how treatment therapies may aid in the management of this disease.
[0003] Osteoarthritis is a chronic, degenerative joint disease that is caused by the progressive inflammation and deterioration of the cartilage, bone, and soft tissue of one or more joints. Rheumatoid arthritis is an autoimmune condition that causes
inflammation and damage to the joints. Both are chronic inflammatory conditions. Because the damage to the joints is progressive and largely irreversible, it is desirable to identify and address the inflammatory process proactively. Unfortunately, biomarker expression in blood has proved difficult to correlate with expression in tissue, making diagnosis difficult before the disease leads to severe pain and irreversible tissue damage.
Summary of the invention
[0004] Six genes that were up-regulated in felines with OA compared to normal geriatric felines were identified. These genes were then measured utilizing the same arthritic felines after consuming the test food. A diet which provides clinical benefit correlating with the reduction in expression of the six genes has also been identified.
[0005] Thus the invention provides in a first embodiment a method of detecting an inflammatory condition in a feline, comprising measuring blood levels of a gene selected from one or more of INDO, ANXAl, MMP8, CD79a, ODCl, and STXBP2, wherein increased expression is correlated with an inflammatory condition.
[0006] In a further embodiment, the invention provides a method of control and/ or prophylaxis of inflammation, or mitigation of inflammatory conditions, particularly arthritis and joint pain, in a feline, comprising identifying the condition by measuring blood expression levels of INDO, ANXAl, MMP8, CD79a, ODCl, and/ or STXBP2, and administering a diet comprising increased levels of one or more of DHA, EPA, methionine, manganese, vitamin C, vitamin E, and/ or L-carnitine, e.g., for a period of at least two weeks.
Detailed Description of the Invention
[0007] The diet for use in the methods herein includes for example, a feline diet comprising increased levels of one or more of DHA, EPA, methionine, manganese, vitamin C, vitamin E, and/ or L-carnitine. e.g., comprising DHA+EPA 0.25 - 5% on a dry weight basis, for example a diet comprising, on a dry weight basis:
DHA + EPA: 0.5-2.5%
Methionine: 1-3% mg/kg,
Manganese: 50-200 ppm
Vitamin C: 75-1000mg/kg
Vitamin E: 500 - 2500 mg/kg
L-carnitine: 100-1500 mg/kg
for example a diet having approximately the nutritional composition of the test diet of Example 1, e.g., having ingredients in the approximately amounts identified in Table 1, +/- 10% on a dry weight basis.
Example 1 - Effect of diet on inflammatory biomarkers in arthritic felines
[0008] This study was conducted to evaluate the effect of a test food on whole blood gene expression profiles when fed to felines with appendicular degenerative joint disease (DJD). Thirty-one domestic short hair felines (initial weight, 4.2 ± 1.27 kg, age, 12.1 ± 2.98 years) with lameness and radiographic changes consistent with DJD were included in the study. All felines were fed a control food for 28 days followed by a test food. The test food contained increased levels of DHA and EPA, methionine,
manganese, Vitamins C and E, and L-carnitine. Whole blood samples were collected on the last day of the control food and after 14 days on the test food. After consuming the test food for 14 days, felines with DJD had decreased expression of the 6 genes (INDO, ANXAl, MMP8, CD79a, ODCl, and STXBP2), which were identified to be up-regulated in DJD versus healthy geriatric felines. These genes are associated with cartilage degradation, B cell function, polyamine synthesis, and protein trafficking. In summary, feeding the test food to felines with DJD resulted in reversal of the gene expression patterns previously observed in the blood of felines with DJD versus healthy geriatric felines after 14 days.
[0009] Thirty-one neutered/ spayed domestic short hair felines were identified for this study. Felines with lameness were radiographed to confirm changes consistent with degenerative joint disease. Felines were considered otherwise healthy by physical exam and serum chemistry profiles. All felines were immunized against feline
panleukopenia, calici and herpes viruses, and rabies, and none had chronic systemic disease on the basis of results of physical examination, complete blood count
determination, serum biochemical analyses, urinalysis, and fecal examination for parasites. Felines were housed with 10 - 12 other felines and food was continuously available throughout the day until their daily caloric requirements were consumed.
Felines were housed in spacious rooms with natural light that varied with seasonal changes. Felines experienced behavioral enrichment through interactions with each other, by daily interaction and play time with caretakers, large windows and sun porches to watch the natural landscape and access to toys. All felines were fed a maintenance control food for 28 days before day 0 collection, followed by the test food. Blood was drawn and collected into PAXgene tubes and stored at -20°C until
evaluation.
[0010] The Partek® GS (Partek Inc., St. Charles, MO) for Gene Expression Data software (Partek Incorporated, 12747 Olive Blvd., Suite 205, St. Louis, Missouri 63141, U.S.A. http:/ / www.partek.com/ partekgs_geneexpression ) was used for data analysis. The Robust Multichip Average (RMA) algorithm (1) was used for background adjustment, normalization, and probe-level summarization of the GeneChip® samples. The
ANOVA analysis was performed to find significant differentially expressed genes between any two groups with a minimal FDR control at 0.1 and a fold change of 1.3 in each direction. Furthermore, the false discovery rate threshold of 0.1 (means that 10% of observations are due to chance) was chosen as the minimum level of acceptable statistical significance. Similar cutoff values were used the RT-PCR analysis of the 74 selected genes for verification of the microarray data.
Table 1: Nutritional values of control and test diet
5.8 7.6
Insoluble fiber, %
0.1 1.7
Soluble fiber, %
0.95 1.04
Calcium, %
0.86 0.78
Phosphorus, %
0.6 1.0
Potassium, %
0.4 0.3
Sodium, %
0.07 0.09
Magnesium, %
0.75 0.96
Chloride, %
3.1 3.6
Linoleic Acid, %
0.13 0.26
Alpha linolenic acid, %
<0.01 0.28
DHA, %
<0.01 0.38
EPA, %
1.5 2.7
Lysine, %
0.92 1.54
Methionine, %
15 97
Manganese, ppm
Vitamin E, IU/kg 104 1215
Vitamin C, ppm 0 174
Taurine, ppm 1230 2857
Carnitine, ppm 21 504
Table 2: RT-PCR analysis of genomic differences in felines with osteoarthritis compared to healthy geriatric felines
Day 14 / Day 0
Gene name Gene Symbol Fold Change P-value
CD79A binding protein 1 CD79A -2.4 0.04
Annexin Al ANXAl -17.0 0.01
Orinthine Decarboyxlase 1 ODCl -2.3 0.01
Indoleamine pyrrole 2,3 dioxygenase INDO -3.2 0.09
Syntax binding protein 2 STXBP2 -2.7 0.06
Matrix metalloproteinase 8 MMP8 -19.2 0.03
[0011] Based on the day 0 comparison of felines with OA and healthy geriatric felines, 6 genes that were significantly up-regulated in OA felines were identified. After switching the OA felines to a test food, these 6 genes (CP79a, INDO, ANXAl, ODCl, STXBP2, and MMP8) were down-regulated after 14 days. In effect, these genes now appeared more like the expression of that found in the normal geriatric felines. The results of the current study showed the 6 genes identified as significantly up-regulated in felines with OA versus normal geriatric felines were down-regulated after consuming a test food. These specific genes may play an essential role in the
development of OA or DJD or the underlying arthritic condition. This data may provide genomic support for the efficacy of the test food in arthritic felines. In agreement with clinical and activity responses measured, arthritic felines fed the test
food had gene expression more similar to normal geriatric felines after consuming the test food.
Claims (8)
1. A method of detecting an inflammatory condition in a feline, comprising measuring blood levels of a gene selected from one or more of INDO, ANXAl, MMP8, CD79a, ODC1, and STXBP2, wherein increased expression is correlated with an
inflammatory condition.
2. The method of claim 1 wherein the inflammatory condition is treated or controlled by administering a diet comprising increased levels of one or more of DHA, EPA, methionine, manganese, vitamin C, vitamin E, and/ or L-carnitine.
3. The method of claim 2 wherein the diet is administered for a period of at least two weeks.
4. The method of claim 2 or 3 wherein the diet is a feline diet comprising increased levels of one or more of DHA, EPA, methionine, manganese, vitamin C, vitamin E, and/ or L-carnitine.
5. The method of claim 4 wherein the diet comprises DHA+EPA 0.25 - 5% on a dry weight basis.
6. The method of claim 5 wherein the diet comprises, on a dry weight basis:
DHA + EPA: 0.5-2.5%
Methionine: 1-3% mg/kg,
Manganese: 50-200 ppm
Vitamin C: 75-1000mg/kg
Vitamin E: 500 - 2500 mg/kg
L-carnitine: 100-1500 mg/kg
7. The method of claim 6 wherein the diet has approximately the nutritional
composition of the test diet of Example 1.
8. The method of any of the foregoing claims wherein the condition to be controlled or treated is osteoarthritis.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33407810P | 2010-05-12 | 2010-05-12 | |
US61/334,078 | 2010-05-12 | ||
PCT/US2011/035731 WO2011143102A1 (en) | 2010-05-12 | 2011-05-09 | Methods of diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in felines |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2011253200A1 true AU2011253200A1 (en) | 2012-11-22 |
AU2011253200B2 AU2011253200B2 (en) | 2014-01-16 |
Family
ID=44278823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2011253200A Ceased AU2011253200B2 (en) | 2010-05-12 | 2011-05-09 | Methods of diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in felines |
Country Status (9)
Country | Link |
---|---|
US (1) | US20130059012A1 (en) |
EP (1) | EP2568823B1 (en) |
JP (1) | JP2013528800A (en) |
CN (1) | CN102883624A (en) |
AU (1) | AU2011253200B2 (en) |
BR (1) | BR112012028643A2 (en) |
CA (1) | CA2797539C (en) |
RU (1) | RU2012153677A (en) |
WO (1) | WO2011143102A1 (en) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6077828A (en) * | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
US8252742B2 (en) * | 2004-12-30 | 2012-08-28 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
AU2006330418B2 (en) * | 2005-12-29 | 2010-07-15 | Hill's Pet Nutrition, Inc. | Compositions and methods for preventing or treating inflammatory bowel disease |
RU2449554C2 (en) * | 2006-02-01 | 2012-05-10 | Нестек С.А. | Food systems and longevity enhancement methods |
CA2679215C (en) * | 2007-02-22 | 2015-11-24 | Hill's Pet Nutrition, Inc. | Compositions and methods for altering gene expression |
CA2685875C (en) * | 2007-05-01 | 2015-10-06 | Hill's Pet Nutrition, Inc. | Methods and compositions for diagnosing osteoarthritis in a feline |
EP2323638B1 (en) * | 2008-07-18 | 2014-05-07 | Hill's Pet Nutrition, Inc. | Compositions and methods for treating osteoarthritis |
-
2011
- 2011-05-09 EP EP11720682.1A patent/EP2568823B1/en not_active Not-in-force
- 2011-05-09 BR BR112012028643A patent/BR112012028643A2/en not_active IP Right Cessation
- 2011-05-09 CA CA2797539A patent/CA2797539C/en not_active Expired - Fee Related
- 2011-05-09 CN CN2011800236339A patent/CN102883624A/en active Pending
- 2011-05-09 AU AU2011253200A patent/AU2011253200B2/en not_active Ceased
- 2011-05-09 US US13/697,051 patent/US20130059012A1/en not_active Abandoned
- 2011-05-09 JP JP2013510202A patent/JP2013528800A/en not_active Ceased
- 2011-05-09 RU RU2012153677/15A patent/RU2012153677A/en unknown
- 2011-05-09 WO PCT/US2011/035731 patent/WO2011143102A1/en active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mahalhal et al. | Oral iron exacerbates colitis and influences the intestinal microbiome | |
Romano et al. | Metabolic, epigenetic, and transgenerational effects of gut bacterial choline consumption | |
Yang et al. | ABO genotype alters the gut microbiota by regulating GalNAc levels in pigs | |
Dong et al. | Effects of dietary threonine supplementation on intestinal barrier function and gut microbiota of laying hens | |
Ilott et al. | Defining the microbial transcriptional response to colitis through integrated host and microbiome profiling | |
JP6078049B2 (en) | Methods for diagnosing, inhibiting and preventing canine inflammation and alleviating inflammatory conditions | |
Coleman et al. | Comparison of the microbiome, metabolome, and lipidome of obese and non-obese horses | |
Gao et al. | A comparison of dynamic distributions of intestinal microbiota between Large White and Chinese Shanxi Black pigs | |
Park et al. | Effects of feeding Original XPC™ to broilers with a live coccidiosis vaccine under industrial conditions: Part 2. Cecal microbiota analysis | |
Just et al. | Lowered dietary phosphorus affects intestinal and renal gene expression to maintain mineral homeostasis with immunomodulatory implications in weaned piglets | |
AU2011253230A1 (en) | Methods for the diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in canines | |
Chleilat et al. | Paternal high protein diet modulates body composition, insulin sensitivity, epigenetics, and gut microbiota intergenerationally in rats | |
Han et al. | Protective effects of Lacticaseibacillus rhamnosus Hao9 on dextran sulphate sodium‐induced ulcerative colitis in mice | |
Bai et al. | Heat stress affects faecal microbial and metabolic alterations of rabbits | |
Dhanasiri et al. | Effects of dietary supplementation with prebiotics and Pediococcus acidilactici on gut health, transcriptome, microbiota, and metabolome in Atlantic salmon (Salmo salar L.) after seawater transfer | |
US20220220540A1 (en) | Methods for predicting equine weight loss propensity | |
CA2797539C (en) | Methods of diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in felines | |
AU2011253200A1 (en) | Methods of diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in felines | |
JPWO2019151515A1 (en) | How to detect early colorectal cancer | |
Wang et al. | Microbiome, transcriptome, and metabolomic analyses revealed the mechanism of immune response to diarrhea in rabbits fed antibiotic-free diets | |
Barszcz et al. | The effect of dietary level of two inulin types differing in chain length on biogenic amine concentration, oxidant-antioxidant balance and DNA repair in the colon of piglets | |
Menard et al. | Noninvasive sampling of the small intestinal chyme for microbiome, metabolome and antimicrobial resistance genes in dogs, a proof of concept | |
Tal Gavriel | The Effect of Obesity and Weight Loss on the Feline Fecal Microbiota, Inflammation and Intestinal Health Markers | |
Allen et al. | eP002: Pilot study of insulin-like growth factor 1 on differing metabolic responders with Phelan-McDermid syndrome: Preliminary results | |
Tan et al. | Characteristics of gut microbiota and metabolomic of Hainan Tunchang pigs at various growth stages |